Anti-tubercular therapy for intraocular tuberculosis: A systematic review and meta-analysis

Surv Ophthalmol. 2016 Sep-Oct;61(5):628-53. doi: 10.1016/j.survophthal.2016.03.001. Epub 2016 Mar 10.


Intraocular tuberculosis remains a diagnostic and management conundrum for both ophthalmologists and pulmonologists. We analyze the efficacy and safety of anti-tubercular therapy (ATT) in patients with intraocular tuberculosis and factors associated with favorable outcome. Twenty-eight studies are included in this review, with a total of 1,917 patients. Nonrecurrence of inflammation was observed in pooled estimate of 84% of ATT-treated patients (95% CI 79-89). There was minimal difference in the outcome between patients treated with ATT alone (85% successful outcome; 95% CI 25-100) and those with concomitant systemic corticosteroid (82%; 95% CI 73-90). The use of ATT may be of benefit to patients with suspected intraocular tuberculosis; however, this conclusion is limited by the lack of control group analysis and standardized recruitment and treatment protocols. We propose further prospective studies to better establish the efficacy of ATT and ascertain the factors associated with favorable treatment outcomes.

Keywords: anti-tubercular therapy; intraocular; tuberculosis; uveitis.

Publication types

  • Meta-Analysis
  • Review
  • Systematic Review

MeSH terms

  • Anti-Inflammatory Agents / therapeutic use*
  • Antitubercular Agents / therapeutic use*
  • Disease Management*
  • Humans
  • Prognosis
  • Tuberculosis, Ocular / diagnosis
  • Tuberculosis, Ocular / drug therapy*


  • Anti-Inflammatory Agents
  • Antitubercular Agents